S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.46
+1.78
+10.67%
ZYME · Zymeworks Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
$28.13
+1.23
(+4.59%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$28.13
$26.92
$28.25
52-WEEK RANGE
$28.13
$16.00
$31.34
What's happening
- ZYME is up 4.59% today, trading at $28.13. — Live quote
- Volume today (49,482) is well below its 3-month average of 775,950. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.62 actual vs. $-0.50 estimated (-25.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 7
Buy 11
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (19 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ZYME
+2.20%
vs S&P 500
-10.57%
1-YEAR RETURN
ZYME
+46.89%
vs S&P 500
+32.33%
6-MONTH RETURN
ZYME
-1.07%
3-MONTH RETURN
ZYME
+11.89%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.62
Est. $-0.50
MISS -25.1%
2026-04-26 (Q1 2026)
$-0.59
Est. $-0.20
MISS -201.3%
2026-01-26 (Q4 2025)
$-0.55
Est. $-0.42
MISS -29.5%
2025-10-26 (Q3 2025)
$-0.26
Est. $-0.33
BEAT +20.6%
Valuation Measures & Ratios
Enterprise Value4$2.16B
Forward P/E522.84
PEG Ratio6—
Price / Sales (TTM1)56.18
Price / Book723.28
EV4 / Revenue58.15
EV4 / EBITDA10.19
Profit Margin-404.00%
Operating Margin-418.99%
Return on Equity (ROE8)-72.07%
Return on Assets (ROA9)-37.06%
Avg Volume (3M)775,950
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $1.90B | $1.87B | $1.29B | $970.1M | $899.4M |
| P/E | -17.81 | -22.28 | -18.46 | -11.04 | -7.38 |
| Price/Sales | 22.76 | 17.70 | 10.78 | 8.73 | 12.43 |
| Price/Book | 23.60 | 11.45 | 4.02 | 2.90 | 2.77 |
| EV/Revenue | 20.61 | 15.39 | 10.24 | 7.85 | 11.37 |
| ROE | -132.47% | -51.40% | -21.80% | -26.26% | -37.49% |
| ROA | -26.82% | -17.58% | -17.56% | -21.51% | -28.63% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short5,291,136
Change from Prior Settlement+7.13%
% of Float—
Days to Cover (Short Ratio)5.55
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +46.9%. Finnhub market metrics ↗
- Latest SEC filing is Form 4, filed 2026-10-09; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -90.6% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -404.0%. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ZYME
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.6M | $2.4M | $27.6M | $48.7M | $27.1M | $16.0M | $19.2M | $10.0M |
| Operating income | -$42.2M | -$47.1M | -$22.1M | -$674.0K | -$25.6M | -$34.2M | -$42.9M | -$37.8M |
| Net income | -$45.0M | -$44.2M | -$19.6M | $2.3M | -$22.6M | -$29.9M | -$37.7M | -$31.7M |
| EPS (diluted) | $-0.62 | $-0.59 | $-0.26 | $0.03 | $-0.30 | $-0.39 | $-0.49 | $-0.42 |
| EPS (basic) | $-0.62 | $-0.59 | $-0.26 | $0.03 | $-0.30 | $-0.39 | $-0.49 | $-0.42 |
| Operating margin | -$919 | -$2.0K | -$80 | -$1 | -$94 | -$214 | -$223 | -$377 |
| Net margin | -$981 | -$1.8K | -$71 | $5 | -$83 | -$187 | -$196 | -$316 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $397.0M | $478.2M | $346.5M | $397.3M | $408.4M | $425.5M | $463.1M | $487.2M |
| Total liabilities | $316.6M | $314.6M | $78.0M | $77.2M | $73.9M | $100.6M | $124.3M | $120.2M |
| Stockholders' equity | $80.4M | $163.6M | $268.5M | $320.1M | $334.5M | $325.0M | $338.8M | $367.0M |
| Total current assets | $298.4M | $385.7M | $248.8M | $291.7M | $296.1M | $306.5M | $300.5M | $343.8M |
| Total current liabilities | $47.2M | $35.6M | $42.3M | $42.0M | $38.5M | $65.1M | $88.3M | $83.9M |
| Cash & equivalents | $179.4M | $244.3M | $41.2M | $64.8M | $98.3M | $76.2M | $66.1M | $122.4M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | $5.9M | $4.7M | $4.6M | $29.4M | $2.6M | $24.6M | $55.8M | $23.7M |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $14.0M | $14.9M | $15.5M | $15.8M | $16.3M | $16.7M | $17.6M | $18.3M |
| Goodwill | $12.0M | $12.0M | $12.0M | $12.0M | $12.0M | $12.0M | $12.0M | $12.0M |
| Intangible assets | $998.0K | $1.2M | $1.4M | $1.4M | $2.0M | $3.4M | $4.6M | $6.4M |
| Deferred revenue (current) | $16.4M | $2.1M | $2.4M | $3.2M | $3.8M | $23.5M | $25.6M | $27.2M |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $278.0K | $278.0K | $278.0K | $278.0K | $828.0K | $856.0K | $923.0K | $929.0K |
| Common stock & paid-in capital | $1.13B | $1.13B | $1.11B | $1.09B | $1.07B | $1.02B | $1.02B | $1.01B |
| Retained earnings | -$1.17B | -$1.07B | -$953.2M | -$886.5M | -$850.7M | -$853.0M | -$830.3M | -$797.8M |
| Accumulated other comprehensive income (loss) | -$6.7M | -$6.6M | -$6.1M | -$6.0M | -$6.3M | -$6.4M | -$7.0M | -$6.0M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$31.9M | -$45.7M | -$10.3M | -$31.4M | $12.1M | -$3.4M | -$41.5M | -$5.9M |
| Investing cash flow | $17.1M | $70.0M | $5.4M | $368.0K | $8.7M | $12.2M | -$6.2M | $72.3M |
| Financing cash flow | -$50.0M | $178.8M | -$18.7M | -$2.5M | $1.3M | $1.3M | -$8.6M | -$15.0M |
| Free cash flow | -$31.9M | -$45.9M | -$10.8M | -$31.8M | $11.6M | -$3.4M | -$41.8M | -$6.8M |
| Capital expenditures | $0 | $216.0K | $581.0K | $410.0K | $514.0K | $16.0K | $314.0K | $899.0K |
| Share-based compensation | $11.3M | $6.9M | $8.8M | $6.9M | $5.9M | $6.4M | $5.0M | $4.7M |
| Deferred income taxes | — | — | $945.0K | — | — | — | $691.0K | — |
| Change in accounts receivable | $1.3M | $36.0K | -$24.7M | $26.7M | -$22.0M | -$31.2M | $31.6M | -$7.9M |
| Purchases of investments | $62.5M | $0 | $56.8M | $35.1M | $70.1M | $34.0M | $53.8M | $52.7M |
| Share repurchases | $51.9M | $76.2M | $25.5M | $16.2M | $0 | $0 | $9.4M | $20.6M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $106.0M | $76.3M | $76.0M | $412.5M | $26.7M |
| Operating income | -$92.5M | -$137.1M | -$138.1M | $130.5M | -$215.6M |
| Net income | -$81.1M | -$122.7M | -$118.7M | $124.3M | -$211.8M |
| EPS (diluted) | $-1.08 | $-1.62 | $-1.72 | $1.90 | $-4.61 |
| EPS (basic) | $-1.08 | $-1.62 | $-1.72 | $1.91 | $-4.11 |
| Operating margin | -$87 | -$180 | -$182 | $32 | -$808 |
| Net margin | -$77 | -$161 | -$156 | $30 | -$794 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $346.5M | $463.1M | $580.9M | $648.7M | $389.1M |
| Total liabilities | $78.0M | $124.3M | $116.1M | $155.8M | $140.0M |
| Stockholders' equity | $268.5M | $338.8M | $464.8M | $493.0M | $249.1M |
| Total current assets | $248.8M | $300.5M | $412.9M | $544.7M | $288.2M |
| Total current liabilities | $42.3M | $88.3M | $55.8M | $95.6M | $71.9M |
| Cash & equivalents | $41.2M | $66.1M | $157.6M | $400.9M | $201.9M |
| Marketable securities (current) | — | — | $216.8M | $91.3M | $50.7M |
| Accounts receivable | $4.6M | $55.8M | $19.5M | $33.4M | $15.6M |
| Marketable securities (non-current) | — | — | $82.1M | $886.0K | $886.0K |
| Property, plant & equipment | $15.5M | $17.6M | $19.8M | $24.7M | $22.8M |
| Goodwill | $12.0M | $12.0M | $12.0M | $12.0M | $12.0M |
| Intangible assets | $1.4M | $4.6M | $7.7M | $8.8M | $3.8M |
| Deferred revenue (current) | $2.4M | $25.6M | $3.7M | $2.4M | $0 |
| Other non-current liabilities | $278.0K | $923.0K | $1.7M | $3.1M | $2.7M |
| Common stock & paid-in capital | $1.11B | $1.02B | $997.2M | $886.3M | $741.1M |
| Retained earnings | -$953.2M | -$830.3M | -$677.4M | -$558.8M | -$683.1M |
| Accumulated other comprehensive income (loss) | -$6.1M | -$7.0M | -$6.6M | -$6.7M | -$6.7M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$33.0M | -$110.1M | -$118.3M | $144.1M | -$192.5M |
| Investing cash flow | $26.7M | $38.8M | -$207.3M | -$53.8M | $144.6M |
| Financing cash flow | -$18.6M | -$20.4M | $81.9M | $108.6M | $8.0M |
| Free cash flow | -$34.5M | -$112.0M | -$120.8M | $136.0M | -$204.9M |
| Capital expenditures | $1.5M | $2.0M | $2.5M | $8.2M | $12.4M |
| Share-based compensation | $28.0M | $17.8M | $8.1M | $4.0M | $10.8M |
| Deferred income taxes | $945.0K | $691.0K | -$757.0K | $1.9M | -$953.0K |
| Change in accounts receivable | -$51.2M | $36.4M | -$13.9M | $17.5M | $266.0K |
| Purchases of investments | $196.1M | $283.7M | $553.2M | $113.0M | $35.1M |
| Share repurchases | $41.7M | $30.1M | $0 | $0 | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ZYME as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers84.0%
Shares Outstanding72,993,313
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 22,970,388 | $600.4M | 31.47% | +0.0% | 2026-08-14 |
| Rubric Capital Management LP | 7,000,000 | $183.0M | 9.59% | +0.0% | 2026-08-14 |
| BlackRock, Inc. | 4,251,030 | $111.1M | 5.82% | -6.7% | 2026-08-07 |
| PERCEPTIVE ADVISORS LLC | 4,182,953 | $109.3M | 5.73% | +19.2% | 2026-08-14 |
| BVF INC/IL | 3,649,142 | $95.4M | 5.00% | -2.3% | 2026-08-14 |
| Morgan Stanley | 2,231,260 | $58.3M | 3.06% | -10.1% | 2026-08-11 |
| BNP Paribas Asset Management Holding S.A. | 1,781,116 | $46.6M | 2.44% | -6.7% | 2026-08-12 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,558,998 | $40.8M | 2.14% | -8.6% | 2026-06-30 |
| Assenagon Asset Management S.A. | 1,252,027 | $32.7M | 1.72% | +72.0% | 2026-07-08 |
| Nextech Invest Ltd. | 1,113,946 | $29.1M | 1.53% | +0.0% | 2026-08-14 |
| State Street Corp | 1,088,216 | $28.4M | 1.49% | +7.6% | 2026-08-07 |
| DIMENSIONAL FUND ADVISORS LP | 994,955 | $26.0M | 1.36% | -12.7% | 2026-08-11 |
| CITADEL ADVISORS LLC | 914,136 | $23.9M | 1.25% | -20.5% | 2026-08-14 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 889,802 | $23.3M | 1.22% | +0.0% | 2026-08-14 |
| FMR LLC | 702,568 | $18.4M | 0.96% | +5.3% | 2026-08-13 |
| GEODE CAPITAL MANAGEMENT, LLC | 692,410 | $18.1M | 0.95% | +4.9% | 2026-08-12 |
| Prosight Management, LP | 674,434 | $17.6M | 0.92% | +0.0% | 2026-08-14 |
| Qube Research & Technologies Ltd | 593,590 | $15.5M | 0.81% | +15.9% | 2026-08-14 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 510,032 | $13.3M | 0.70% | +2.0% | 2026-06-30 |
| Redmile Group, LLC | 491,654 | $12.9M | 0.67% | +0.0% | 2026-08-14 |
| Capricorn Fund Managers Ltd | 486,529 | $12.7M | 0.67% | -51.7% | 2026-07-24 |
| Goldman Sachs Group Inc | 470,822 | $12.3M | 0.65% | -21.5% | 2026-08-14 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 418,497 | $10.9M | 0.57% | -43.7% | 2026-08-13 |
| DEUTSCHE BANK AG\ | 397,190 | $10.4M | 0.54% | -56.9% | 2026-08-07 |
| Hillsdale Investment Management Inc. | 382,922 | $10.0M | 0.52% | +10.8% | 2026-08-11 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-06-26 to 2026-10-09
Recent transactions
- Insiders have net sold 13,832 shares over the last 182 days, across 0 purchases and 1 sale.
- Most recent: Schayowitz Adam (EVP, Head of R&D) — Option exercise of 37,037 shares on 2026-10-09.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)13,832 sh(1 txns)
Net Shares-13,832
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Schayowitz Adam | EVP, Head of R&D | Option exercise | 2026-10-09 | 37,037 |
| Hollywood Mark | EVP & Chief Operating Officer | Grant / award | 2026-07-06 | 939 |
| Smith Jeffrey T L | EVP & Chief Medical Officer | Option exercise | 2026-01-12 | 17,666 |
| Moore Paul Andrew | Chief Scientific Officer | Option exercise | 2026-01-12 | 17,666 |
| Galbraith Kenneth | Chair & CEO | Option exercise | 2026-01-12 | 64,000 |
| PATTERSON LEONE D | EVP, Chief Bus & Fin Officer | Grant / award | 2026-01-06 | 459 |
| Ciongoli Gregory Austin | Reporting person | Grant / award | 2025-08-12 | 415,000 |
| EcoR1 Capital, LLC | Director | In-the-money option exercise | 2025-06-26 | 5,086,480 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-09 | Schayowitz Adam | EVP, Head of R&D | Option exercise | 37,037 | $0.00 |
| 2026-10-09 | Schayowitz Adam | EVP, Head of R&D | Open market sale | 13,832 | $25.85 |
| 2026-07-06 | Hollywood Mark | EVP & Chief Operating Officer | Grant / award | 939 | $22.22 |
| 2026-01-12 | Hollywood Mark | EVP & Chief Operating Officer | Option exercise | 17,666 | $0.00 |
| 2026-01-12 | Hollywood Mark | EVP & Chief Operating Officer | Open market sale | 6,120 | $22.67 |
| 2026-01-12 | Smith Jeffrey T L | EVP & Chief Medical Officer | Option exercise | 17,666 | $0.00 |
| 2026-01-12 | Smith Jeffrey T L | EVP & Chief Medical Officer | Open market sale | 9,310 | $22.67 |
| 2026-01-12 | Moore Paul Andrew | Chief Scientific Officer | Option exercise | 17,666 | $0.00 |
| 2026-01-12 | Moore Paul Andrew | Chief Scientific Officer | Open market sale | 9,560 | $22.67 |
| 2026-01-12 | Galbraith Kenneth | Chair & CEO | Option exercise | 64,000 | $0.00 |
| 2026-01-12 | Galbraith Kenneth | Chair & CEO | Open market sale | 30,424 | $22.67 |
| 2026-01-06 | PATTERSON LEONE D | EVP, Chief Bus & Fin Officer | Grant / award | 459 | $10.55 |
| 2026-01-05 | Smith Jeffrey T L | EVP & Chief Medical Officer | Option exercise | 20,000 | $0.00 |
| 2026-01-05 | Smith Jeffrey T L | EVP & Chief Medical Officer | Open market sale | 10,538 | $25.10 |
| 2026-01-05 | Galbraith Kenneth | Chair & CEO | Option exercise | 47,668 | $0.00 |
| 2026-01-05 | Galbraith Kenneth | Chair & CEO | Open market sale | 22,657 | $25.10 |
| 2026-01-05 | Galbraith Kenneth | Chair & CEO | Option exercise | 66,666 | $0.00 |
| 2026-01-05 | Galbraith Kenneth | Chair & CEO | Open market sale | 31,686 | $25.10 |
| 2026-01-05 | Moore Paul Andrew | Chief Scientific Officer | Option exercise | 17,168 | $0.00 |
| 2026-01-05 | Moore Paul Andrew | Chief Scientific Officer | Open market sale | 9,289 | $25.10 |
| 2026-01-05 | Moore Paul Andrew | Chief Scientific Officer | Option exercise | 20,000 | $0.00 |
| 2026-01-05 | Moore Paul Andrew | Chief Scientific Officer | Open market sale | 10,821 | $25.10 |
| 2025-12-22 | Galbraith Kenneth | Chair & CEO | Option exercise | 100,000 | $0.00 |
| 2025-12-22 | Galbraith Kenneth | Chair & CEO | Open market sale | 47,528 | $27.02 |
| 2025-08-12 | Ciongoli Gregory Austin | Reporting person | Grant / award | 415,000 | $12.02 |
| 2025-06-26 | EcoR1 Capital, LLC | Director | In-the-money option exercise | 5,086,480 | $0.00 |
| 2025-06-26 | EcoR1 Capital, LLC | Director | Tax withholding | 41 | $12.71 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 08:39 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-09 | 4 | 2026-10-09 | View on SEC.gov → |
| 2026-09-23 | 8-K | 2026-09-23 | View on SEC.gov → |
| 2026-08-25 | 8-K | 2026-08-25 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-07-06 | 4 | 2026-07-06 | View on SEC.gov → |
| 2026-06-29 | 8-K | 2026-06-28 | View on SEC.gov → |
| 2026-05-15 | 4 | 2026-05-13 | View on SEC.gov → |
| 2026-05-14 | 8-K | 2026-05-14 | View on SEC.gov → |
| 2026-05-07 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-07 | 8-K | 2026-05-07 | View on SEC.gov → |
| 2026-04-10 | 4 | 2026-04-09 | View on SEC.gov → |
Recent news
Headlines about ZYME (Zymeworks Inc.). Links open the publisher — we don’t host full articles.
-
Zymeworks Q3 2026 Earnings Date and Estimates
MarketBeat · 2026-10-20 -
Zymeworks appoints Suzanne Monahan. Truist sets USD 34 target for Zymeworks stock
AD HOC NEWS · 2026-10-20 -
Zymeworks Inc. (ZYME) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
Zymeworks Inc. (ZYME) stock price, news, quote and history
Yahoo Finance UK · 2026-10-20 -
Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma
Yahoo · 2026-10-19 -
A once-daily COPD treatment gets a new commercial lead at Zymeworks
Stock Titan · 2026-10-19 -
Zymeworks schedules November 9 results: Truist targets Zymeworks stock at USD 34.00
AD HOC NEWS · 2026-10-18 -
Assenagon Asset Management S.A. Buys 256,042 Shares of Zymeworks Inc. $ZYME
MarketBeat · 2026-10-18
No headlines in this category right now — try “All”.